組織診斷市場規模、佔有率、成長分析（按產品類型、按技術、按疾病類型、按方式、按最終用戶、按地區）- 產業預測 2025-2032

2023 年全球組織診斷市場規模價值 54 億美元，預計將從 2024 年的 58.6 億美元成長到 2032 年的 113.5 億美元，預測期內（2025-2032 年）的複合年成長率為 8.6%。

受癌症發病率上升的推動，組織診斷市場預計將大幅成長。由於資源被轉移到控制病毒上，COVID-19 疫情導致診斷檢測暫時中斷，但隨著醫療保健系統適應新常態，市場正在復甦。人們對準確診斷和疾病監測的需求日益成長，尤其是對癌症。解剖病理學的進步推動了臨床病理學的不斷擴展，解剖病理學和分子病理學的融合日益突出。液態切片在癌症診斷中的應用正在增加，計算病理學日益成長的重要性凸顯了生物資訊學的重要性。在過去的二十年裡，該領域的診斷工具得到了擴展，徹底改變了病理學家和臨床醫生的實踐。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術分析

組織診斷市場規模（按產品類型和複合年成長率） (2025-2032)

• 市場概覽
• 耗材
  • 抗體
  • 套件
  • 試劑
  • 探測
• 裝置
  • 玻片染色系統
  • 掃描器
  • 組織處理系統
  • 其他儀器

組織診斷市場規模（依技術及複合年成長率） (2025-2032)

• 市場概覽
• 免疫組織化學
• 原位雜合技術
• 原發染色及特殊染色
• 解剖病理學
• 分子病理學
• 數位病理學和工作流程管理
• 特殊染色

組織診斷市場規模（按疾病類型和複合年成長率）（2025-2032）

• 市場概覽
• 乳癌
• 胃癌
• 淋巴瘤
• 攝護腺癌
• 非小細胞肺癌
• 其他

組織診斷市場規模（按方式和複合年成長率） (2025-2032)

• 市場概覽
• 臨床
• 製藥/CRO/研究市場

組織診斷市場規模（按最終用戶和複合年成長率分類）（2025 年至 2032 年）

• 市場概覽
• 醫院
• 研究部門
• 製藥公司
• 合約研究組織（CRO）
• 其他

組織診斷市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific Inc.（USA）
• Siemens Healthineers（Germany）
• Danaher Corporation（USA）
• bioMerieux SA（France）
• QIAGEN NV（Netherlands）
• Becton, Dickinson and Company（BD）（USA）
• Merck KGaA（Germany）
• GE Healthcare（USA）
• BioGenex Laboratories（USA）
• Cell Signaling Technology, Inc.（USA）
• Bio SB（USA）
• DiaGenic ASA（Norway）
• Agilent Technologies（USA）
• Fujirebio Inc.（Japan）
• Tecan Group Ltd.（Switzerland）
• STRATEC SE（Germany）
• Seegene Inc.（South Korea）
• Leica Biosystems（Germany）

結論和建議

Global Tissue Diagnostics Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 5.86 billion in 2024 to USD 11.35 billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The tissue diagnostics market is poised for significant growth driven by the rising incidence of cancer. Although the COVID-19 pandemic temporarily hindered diagnostic testing due to resource allocation towards virus containment, the market is rebounding as healthcare systems adapt to new normals. The demand for precise diagnosis and disease monitoring, particularly for cancer, is escalating. Advances in anatomic pathology are fostering the continuous expansion of clinical pathology, while the integration of anatomical and molecular pathology is increasingly evident. The adoption of liquid biopsies for cancer diagnosis is rising, and the growing relevance of computational pathology emphasizes the importance of bioinformatics. Over the past two decades, the sector has seen enhanced diagnostic tools, revolutionizing the practice for pathologists and clinicians.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tissue Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tissue Diagnostics Market Segments Analysis

Global Tissue Diagnostics Market is segmented by Product Type, Technology, Disease Type, Modality, End-user and region. Based on Product Type, the market is segmented into Consumables and Instruments. Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Anatomic Pathology, Molecular Pathology, Digital Pathology & Workflow Management and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer and Others. Based on Modality, the market is segmented into Clinical and Pharma / CRO / Research Market. Based on End-user, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tissue Diagnostics Market

A significant driving force behind the expansion of the global tissue diagnostics market is the rising incidence of chronic diseases, notably cancer. With cancer rates escalating worldwide, the need for swift and precise diagnostic solutions becomes crucial, as early detection significantly increases the likelihood of successful treatment. Innovations in tissue diagnostics, such as immunohistochemistry and molecular pathology, have enhanced the ability of healthcare professionals to identify various tumor types and subtypes accurately. The growing demand for reliable diagnostic tools compels healthcare providers to invest in cutting-edge tissue diagnostics technologies, thereby fostering market growth and enhancing the quality of care for cancer patients.

Restraints in the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market faces significant restraint due to the high costs associated with modern tissue diagnostic techniques. Advanced diagnostic tools and methodologies often come with substantial price tags that can be unaffordable for smaller hospitals and laboratories. The expenses related to equipment, training, and ongoing maintenance further complicate the situation. This financial barrier can hinder access to the latest diagnostic tests, particularly in developing nations where healthcare resources are limited. Consequently, the slow adoption of cutting-edge tissue diagnostics in certain areas restricts the availability of accurate diagnostic tools for patients, impeding overall market growth in this sector.

Market Trends of the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market is witnessing a significant trend towards personalized healthcare, driven by an increasing emphasis on tailored therapies that cater to individual genetic profiles. This shift reflects the need for advanced diagnostic tools capable of identifying specific biomarkers critical for accurate disease characterization. With advancements in genetic profiling and molecular diagnostics, healthcare professionals are equipped to design customized treatment plans that enhance patient outcomes. Consequently, this demand is propelling innovation within the tissue diagnostics sector, as stakeholders strive to develop more precise and effective diagnostic technologies, ultimately leading to improved patient care and a more targeted approach to treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Tissue Diagnostics Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Consumables
  • Antibodies
  • Kits
  • Reagents
  • Probes
• Instruments
  • Slide-staining Systems
  • Scanners
  • Tissue-processing Systems
  • Other Instruments

Global Tissue Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunohistochemistry
• In Situ Hybridization
• Primary & Special Staining
• Anatomic Pathology
• Molecular Pathology
• Digital Pathology & Workflow Management
• Special Staining

Global Tissue Diagnostics Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-small Cell Lung Cancer
• Others

Global Tissue Diagnostics Market Size by Modality & CAGR (2025-2032)

• Market Overview
• Clinical
• Pharma / CRO / Research Market

Global Tissue Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Others

Global Tissue Diagnostics Market Size & CAGR (2025-2032)

• North America (Product Type, Technology, Disease Type, Modality, End-user)
  • US
  • Canada
• Europe (Product Type, Technology, Disease Type, Modality, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Disease Type, Modality, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Disease Type, Modality, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Disease Type, Modality, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio SB (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaGenic ASA (Norway)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STRATEC SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations